{"id":"https://openalex.org/W2014121980","doi":"https://doi.org/10.1016/j.bmcl.2005.03.045","title":"2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR","display_name":"2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR","publication_year":2005,"publication_date":"2005-04-13","ids":{"openalex":"https://openalex.org/W2014121980","doi":"https://doi.org/10.1016/j.bmcl.2005.03.045","mag":"2014121980","pmid":"https://pubmed.ncbi.nlm.nih.gov/15863320"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmcl.2005.03.045","doi":"https://doi.org/10.1016/j.bmcl.2005.03.045","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2005.03.045","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017389980","display_name":"Paul Graham Wyatt","orcid":"https://orcid.org/0000-0002-0397-245X","observed_orcids":["https://orcid.org/0000-0002-0397-245X"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul G. Wyatt","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084090391","display_name":"Michael J. Allen","orcid":"https://orcid.org/0000-0002-8746-9957","observed_orcids":["https://orcid.org/0000-0002-8746-9957"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael J. Allen","raw_affiliation_strings":["ADCP-Harlow Research 2, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ADCP-Harlow Research 2, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031714532","display_name":"Alan D. Borthwick","orcid":"https://orcid.org/0000-0002-6740-4232","observed_orcids":["https://orcid.org/0000-0002-6740-4232"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Alan D. Borthwick","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053722971","display_name":"Dave E. Davies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dave E. Davies","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029454282","display_name":"Anne M. Exall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anne M. Exall","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068162331","display_name":"Richard J. D. Hatley","orcid":"https://orcid.org/0000-0002-3172-2511","observed_orcids":["https://orcid.org/0000-0002-3172-2511"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Richard J.D. Hatley","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070992274","display_name":"Wendy R. Irving","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Wendy R. Irving","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004977280","display_name":"David G. Livermore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David G. Livermore","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081934786","display_name":"Neil D. Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Neil D. Miller","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080499158","display_name":"Fabrizio Nerozzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fabrizio Nerozzi","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090621178","display_name":"Steve L. Sollis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Steve L. Sollis","raw_affiliation_strings":["Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037891192","display_name":"Anna Katrin Szardenings","orcid":"https://orcid.org/0000-0002-9887-7868","observed_orcids":["https://orcid.org/0000-0002-9887-7868"]},"institutions":[{"id":"https://openalex.org/I4210151439","display_name":"Affymax (United States)","ror":"https://ror.org/0505r1x13","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151439"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Katrin Szardenings","raw_affiliation_strings":["Affymax Research Institute, 3410 Central Expressway, Santa Clara, CA 95051, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affymax Research Institute, 3410 Central Expressway, Santa Clara, CA 95051, USA","institution_ids":["https://openalex.org/I4210151439"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5031714532"],"corresponding_institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"],"apc_list":{"value":3880,"currency":"USD","value_usd":3880},"apc_paid":null,"fwci":8.0208,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.97186334,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"15","issue":"10","first_page":"2579","last_page":"2582"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11541","display_name":"Neuroendocrine regulation and behavior","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/3207","display_name":"Social Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11541","display_name":"Neuroendocrine regulation and behavior","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/3207","display_name":"Social Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.02850000001490116,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/2-5-diketopiperazines","display_name":"2,5-diketopiperazines","score":0.9710000157356262},{"id":"https://openalex.org/keywords/oxytocin-antagonist","display_name":"oxytocin antagonist","score":0.9200000166893005},{"id":"https://openalex.org/keywords/oxytocin-receptor","display_name":"oxytocin receptor","score":0.9380000233650208},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.972000002861023},{"id":"https://openalex.org/keywords/stereochemistry","display_name":"stereochemistry","score":0.9850000143051147},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.656000018119812},{"id":"https://openalex.org/keywords/receptor-antagonists","display_name":"receptor antagonists","score":0.6159999966621399},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.41600000858306885}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.9038991928100586},{"id":"https://openalex.org/C2909663711","wikidata":"https://www.wikidata.org/wiki/Q17118718","display_name":"Diketopiperazines","level":2,"score":0.8118979334831238},{"id":"https://openalex.org/C2776176026","wikidata":"https://www.wikidata.org/wiki/Q169960","display_name":"Oxytocin","level":2,"score":0.7841657400131226},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.6730667948722839},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6589256525039673},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.5783149003982544},{"id":"https://openalex.org/C114373084","wikidata":"https://www.wikidata.org/wiki/Q273499","display_name":"Chemical synthesis","level":3,"score":0.5678130388259888},{"id":"https://openalex.org/C116073593","wikidata":"https://www.wikidata.org/wiki/Q864491","display_name":"Biological activity","level":3,"score":0.45917606353759766},{"id":"https://openalex.org/C181612422","wikidata":"https://www.wikidata.org/wiki/Q14908140","display_name":"Oxytocin receptor","level":3,"score":0.45061057806015015},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4351566731929779},{"id":"https://openalex.org/C24961977","wikidata":"https://www.wikidata.org/wiki/Q225972","display_name":"Bicyclic molecule","level":2,"score":0.4347570538520813},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3450966775417328},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.32537901401519775},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2956724166870117},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2579777240753174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.10915657877922058},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018045","descriptor_name":"Receptors, Oxytocin","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.bmcl.2005.03.045","doi":"https://doi.org/10.1016/j.bmcl.2005.03.045","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2005.03.045","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:15863320","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15863320","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry letters","raw_type":"Journal Article"},{"id":"pmh:oai:discovery.dundee.ac.uk:openaire_cris_publications/1d2f4061-dcf3-4983-86b6-ccec876eaab7","doi":null,"is_oa":false,"landing_page_url":"https://discovery.dundee.ac.uk/en/publications/1d2f4061-dcf3-4983-86b6-ccec876eaab7","pdf_url":null,"source":{"id":"https://openalex.org/S4306400523","display_name":"Discovery Research Portal (University of Dundee)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177639307","host_organization_name":"University of Dundee","host_organization_lineage":["https://openalex.org/I177639307"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Wyatt, P G, Allen, M J, Borthwick, A D, Davies, D E, Exall, A M, Hatley, R J D, Irving, W R, Livermore, D G, Miller, N D, Nerozzi, F, Sollis, S L & Szardenings, A K 2005, '2,5-Diketopiperazines as potent and selective oxytocin antagonists 1 : identification, stereochemistry and initial SAR', Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 10, pp. 2579-2582. https://doi.org/10.1016/j.bmcl.2005.03.045","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:ueaeprints.uea.ac.uk:46735","doi":null,"is_oa":false,"landing_page_url":"https://ueaeprints.uea.ac.uk/id/eprint/46735/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400384","display_name":"UEA Digital Repository (University of East Anglia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1118541","host_organization_name":"University of East Anglia","host_organization_lineage":["https://openalex.org/I1118541"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.5683000087738037,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W1967133800","https://openalex.org/W1967942256","https://openalex.org/W1994383015","https://openalex.org/W2004986413","https://openalex.org/W2023565333","https://openalex.org/W2046747066","https://openalex.org/W2051187999","https://openalex.org/W2084316181","https://openalex.org/W4243567911"],"related_works":["https://openalex.org/W1988456626","https://openalex.org/W4235910770","https://openalex.org/W2082473757","https://openalex.org/W2051187999","https://openalex.org/W2084316181","https://openalex.org/W1972808041","https://openalex.org/W2007626776","https://openalex.org/W2023254218","https://openalex.org/W2921962739","https://openalex.org/W2093226508"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":9}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}